James Aloysius Brady, Director at Xeris Biopharma Holdings, Inc. (XERS), sold 10,834 shares at $5.54 ($60K) on 2026-03-30, disclosed to the SEC on 2026-04-01.
Scheduled sale ($60k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.